We present an overview of Runx involvement in regulatory mechanisms that are requisite for fidelity of bone cell growth and differentiation, as well as for skeletal homeostasis and the structural and functional integrity of skeletal tissue. Runx-mediated control is addressed from the perspective of support for biological parameters of skeletal gene expression. We review recent findings that are consistent with an active role for Runx proteins as scaffolds for integration, organization and combinatorial assembly of nucleic acids and regulatory factors within the three-dimensional context of nuclear architecture.
Introduction
Skeletal development and bone remodeling require stringent control of gene activation and suppression in response to physiological cues. The fidelity of skeletal gene expression necessitates integrating a broad spectrum of regulatory signals that govern the commitment of osteoprogenitor and chondroprogenitor stem cells to the bone cell lineage and proliferation and differentiation of osteoblasts, as well as maintenance of the bone phenotype in osteocytes residing in a mineralized bone extracellular matrix. The requirements for short-term developmental and sustained phenotypic expression of cell growth and bone-related genes are accommodated by the selective utilization of promoter regulatory elements. The extent to which genes are transcribed is determined by the temporal/spatial orchestration of combinatorial protein/DNA and protein/protein interactions that control assembly, organization and activity of the regulatory machinery for physiological responsiveness. Runx/Cbfa/AML (runt homology domain) proteins play a pivotal role in governing physiologically responsive control of skeletal genes. Aberrant expression of Runx proteins has been linked to, in an obligatory manner, perturbations in transcription and post-transcriptional regulation that are associated with developmentally compromised skeletogenesis and skeletal disease.
We will present an overview of Runx involvement in regulatory mechanisms that are requisite for fidelity of bone cell growth and differentiation, as well as for expression of genes to sustain skeletal homeostasis and the structural and functional integrity of skeletal tissue. Runx-mediated control will be addressed from the perspective of support for biological parameters of skeletal gene expression. We will review recent findings that are consistent with an active role for Runx proteins as scaffolds for integration, organization and combinatorial assembly of nucleic acids and regulatory factors within the three-dimensional context of nuclear architecture. Such properties endow Runx factors with the specialized functions required for a transcriptional activator that controls a program of gene expression for cell commitment, progression of differentiation and organogenesis.
Runx proteins mediate transcriptional control of bone cell differentiation

Developmental expression of the osteoblast phenotype
The combined application of molecular, cellular, biochemical and in vivo genetic approaches have established a progressive expression of cell growth and phenotypic genes that supports bone cell differentiation (Figure1 and reviewed in Karsenty, 2003; Zhang et al., 2003) . Transcriptional control is required for commitment of progenitor cells to the osteoblast lineage and to exclude options for divergence towards chondrogenesis, myogenesis and adipogenesis. Sequential establishment of the osteoblast phenotype proceeds through three well-characterized developmental periods where regulatory checkpoints monitor competency for developmental progression. Early-stage osteoblasts predominantly express genes to support competency for proliferation and cell cycle progression as well as extracellular matrix biosynthesis. Phenotype-related genes are suppressed during the growth period. Runx1 is present in proliferating osteoprogenitor cells and in pluripotent mesenchymal stromal cells. Runx2 functions in a lineage direction through transactivation and repression. At the first developmental transition, exit The osteoblast growth and differentiation program can be divided into four distinct stages based on different markers expressed at each stage: proliferation of osteoblasts is marked by the induction of various cell cycle markers that include histones; extracellular matrix maturation is characterized by the expression of extracellular matrix-related proteins that include collagen; mineralization of osteoblasts require induction of osteocalcin and other genes. Eventually osteoblasts undergo apoptosis. Importantly, most of these gene markers are either upregulated (shown in green) or suppressed (shown in red) in a Runx-dependent manner; other genes are shown in blue. (b) Progression through the osteoblast lineage from a pluripotent mesenchymal cell to a mature osteocyte is regulated by physiological signals, including, but not limited to, transforming growth factor beta (TGFb), bone morphogenetic protein (BMP), vitamin D and glucocorticoids. Each of the osteoblast subpopulations (depicted as gold-colored cells in the middle of the figure) has many common features, but exhibits unique properties/functions and expresses osteoblast phenotypic genes to a varying extent. Typically, a preosteoblast goes through three morphologically and phenotypically distinct stages to become a mature osteoblast (shown as immunohistochemical micrographs of trypan blue staining (proliferation), alkaline phosphatase activity (matrix maturation) and von Kossa staining for calcium content (mineralization)). In addition to extracellular signals, several transcription factors control the fate of the osteoblastic lineage. Developmental expression of many transcription factors that influence osteoblast differentiation is shown in the bottom. The thickness of the lines represent relative cellular levels of the proteins at the indicated stages from the cell cycle is coupled with continued extracellular matrix biosynthesis as well as with the postproliferative downregulation of proliferation-linked genes and selective activation of genes associated with the maturation and organization of the bone extracellular matrix. A second regulatory transition mediates initiation of gene expression for extracellular matrix mineralization and for sustained structural and functional integrity of bone tissue. During osteoblast differentiation, there is a striking change from cuboidal morphology of the osteoblast to the stellate morphology of the osteocyte, which supports a mechanosensory transduction of regulatory signals in bone cells and tissue.
Complex and interdependent gene regulatory mechanisms support physiological responsiveness throughout the stages of osteoblast differentiation. Equally important, growth factors, developmental regulatory proteins, steroid hormones, cytokines and polypeptide hormone-mediated signaling cascades continue to be operative in differentiated osteoblast lineage cells to interface bone formation and remodeling for bone homeostasis.
Runx1, 2 and 3 contribute to osteogenesis
Runx transcription factors contribute to regulatory mechanisms that are operative throughout osteoblast differentiation and are required to modulate expression of target genes at key developmental transitions. Runx2 is principally linked to osteoblast proliferation and differentiation and is obligatory for regulation of skeletal genes, hypertrophic chondrocytes as well as endochondral and intramembraneous bone formation (Komori et al., 1997; Mundlos et al., 1997; Otto et al., 1997) and skeletal development. Runx1 is largely associated with hematopoiesis, and Runx3 primarily controls neurogenesis (Levanon et al., 2002) and functions as a tumor suppressor of gastric cancer Levanon et al., 2003) . However, several lines of compelling in vitro and in vivo evidence indicate involvement of the three Runx factors in skeletogenesis (Levanon et al., 2001; . Mechanistically and from the perspective of physiological control, Runx1, 2 and 3 appear to impact on bone cell growth as well as tissue-specific transcription.
Runx2 is the principal osteogenic master switch
A prominent role for Runx2 in osteogenesis is initially observed when pluripotent mesenchymal stem cells are committed to the bone cell lineage prior to expression of the osteoblast phenotype (Ducy et al., 1997; Lengner et al., 2001) . Runx2 expression increases during osteoblast differentiation validating involvement in maturation of the osteoblast (Banerjee et al., 1997 (Banerjee et al., , 2001 ). Subsequent to Runx2-mediated commitment to osteogenesis, establishment of the bone cell phenotype is reinforced by Osterix (Nakashima et al., 2002) . Consistent with competency of Runx2 to direct mesenchymally derived progenitor cells towards the phenotype for bone formation, PPARg and CEBPa (Mueller et al., 2002; Tang et al., 2003) are 'master switches' for adipogenesis and SOX9 triggers chondrogenesis (de Crombrugghe et al., 2000) . The prominent involvement of Runx2 in the control of osteogenic commitment is indicated by evidence that the regulatory protein activates bone phenotypic genes in pluripotent cells, redirects a committed premuscle cell to the osteoblast lineage (Lee et al., , 2000 and inhibits the adipogenic phenotype (Gori et al., 1999) .
A parameter of specificity for Runx2 activity may be indicated by preferential high-level expression of the type II isoform (regulated by the P1 promoter) in postproliferative osteoblasts (Figure 2 ). Type I and type II isoforms are initially expressed in osteoprogenitor From the perspective of functional involvement in skeletogenesis and bone remodeling, biochemical, molecular and in vivo genetic approaches have documented the requirements for stringent regulation of Runx2 expression in a manner that is compatible with developmentally defined regulatory mechanisms and stage-specific parameters of bone cell differentiation. Biochemical and histochemical analysis directly demonstrate significant levels of Runx2 in bone marrow and specifically in osteoprogenitor/osteoblast lineage cells that are further elevated during mineral deposition in hypertrophic chondrocytes and mature, fully differentiated osteoblasts (Banerjee et al., 1997 (Banerjee et al., , 2001 Ducy et al., 1997) . Runx2 is initially detected during embryogenesis on day 9.5 in the notochord and at day 10.5 in the mesoderm that is destined to become shoulder bone. By day 11.5, Runx2 is strongly expressed in mesenchymal cells surrounding cartilagenous condensation and in all developing skeletal elements . While Runx2 is robustly expressed during early embryogenesis, prior to initial formation of bone tissue, functional relevance at this stage of skeletal development remains unclear. However, the onset of Runx expression appears to be responsive to BMP signaling or to regulation of the osteochondroprogenitor cell pool.
Runx nullizygous mice completely lack both intermembraneous and endochondral ossification and die at birth Komori et al., 1997; Otto et al., 1997) . Calvarial-derived cells from Runx2-deficient mice express very low levels of early-stage osteoprogenitor markers (e.g. alkaline phosphatase and osteonectin), but not osteopontin and osteocalcin, which are the markers for immature and mature osteoblasts, respectively (Komori et al., 1997) . Taken together, these findings indicate the requirement of Runx2 for commitment to the osteogenic lineage and support final progression to the mature osteocyte and expression of obligatory genes for mineralization of the bone extracellular matrix. Osterix, a BMP2-inducible Kruppel-like SP-1 binding factor, is a transcriptional regulator for the final stages of bone tissue formation. Osterix null mice have normal Runx levels, indicating that osterix is a downstream target of Runx2. Multiple lines of evidence illustrate that Runx2 is the earliest transcription factor that is essential for bone formation (Komori et al., 1997; Otto et al., 1997; Ryoo et al., 1997; Lee et al., 1999; Aubin and Triffitt, 2002; Komori, 2002; Stricker et al., 2002; Vaes et al., 2002) and that alone, Runx is insufficient to support completion of osteoblast differentiation.
Further understanding of Runx contributions to skeletogenesis has emerged from studies in which Runx2 was expressed under the control of either the collagen Type I promoter that exhibits activity which is restricted to osteoblast lineage cells or under the chondrocyte-specific collagen type II promoter. Although these approaches established a role for Runx2 in cellular maturation at the growth plate (Takeda et al., 2001; Ueta et al., 2001; Stricker et al., 2002) , a lesson gained from these transgenic mouse models is that misexpression and high cellular levels of a transcription factor in a cell committed to a nonosseous phenotype that is not physiologically controlled by Runx2 (e.g. arresting chondrocytes) result in severe disruption of endochondral bone formation. Osteopenia is an undesirable consequence of the unregulated expression of Runx2 in osteoblasts under the strong control of a collagen type 1 promoter . There is a stringent requirement for the regulation of Runx2 cellular levels and physiologically responsive control must be maintained for normal bone formation and turnover.
Runx2 is additionally involved in differentiation of nonosseous tissues. Runx2 expression is responsive to IGF1 in endothelial cells where expression appears to contribute to the ability of these cells to form tubular vessels. A dominant-negative form of Runx2 limits migration and invasion, as well as growth arrest and differentiation. Runx2 also regulates cell migration and vascular invasion in bone (Sun et al., 2001; Zelzer et al., 2001) . These findings are consistent with an emerging role for Runx2 in cell fate determination in nonosteogenic lineage cells.
Runx1 and 3 support skeletal development and differentiation
While Runx2 is the principal skeletal Runx family transcription factor, Runx1 and Runx3 are expressed in bone cells, and in vivo genetic data support involvement in skeletal development and differentiation. Runx1 expression has been identified in perichondrium, periosteum and calvarial sutures during embryonic development and is retained in these tissues throughout postnatal life in the mouse . In a gene replacement model in which the LacZ reporter sequence was inserted into the C terminus of Runx1 by homologous recombination , the heterozygous mice (Runx1 LZ/ þ ) exhibit Runx1 expression in tissues related to skeletal development. Runx1 expression may be functionally associated with lineage selection and may participate in maintaining the phenotype of undifferentiated cells, thereby contributing to the initial stages of skeletogenesis and continued bone renewal in the adult. Ex vivo studies of cultured mesenchymal stem cells from Runx1 LZ/ þ mice indicate that Runx1 expression correlates with early stages of chondrocyte and osteoblast differentiation, but a subsequent decrease in Runx1 expression occurs in mature chondrocytes and osteoblasts/osteocytes. These findings suggest that Runx1 contributes to the early stages of skeletogenesis and development of the progenitor tissue that support bone formation in the adult.
Significant levels of Runx3 are detected in osteoblasts throughout the cell cycle . Runx3, like Runx2, is highly expressed in prehypertrophic and hypertrophic chondrocytes, although functional involvement in the skeleton is unresolved (Levanon et al., 2001) . Runx3 cooperates with SMADS and C/EBPa to activate transcription of target genes synergistically that directly influence skeletogenesis (Westendorf et al., 1998; Hanai et al., 1999) . Runx3 null mice establish a requirement of Runx for neurogenesis of dorsal root ganglia and the development of proprioceptive neurons (Levanon et al., 2002; Li et al., 2002) . Posture abnormalities in Runx3 null mice and severe limb ataxia characterized by uncoordinated gait reflect the absence of proprioceptive neurons and consequent disruption of the synaptic stretch reflex circuit.
Despite compelling evidence for the expression of Runx1, 2 and 3 in bone cells, the linkages between Runx1 and 3 expression with regulatory mechanisms that control bone cell differentiation have not been clarified. The striking differences in promoter organization and subtleties in the three Runx proteins may provide options for increasing the scope of Runxmediated control.
Runx target genes provide a signature for obligatory gene expression that controls bone cell proliferation and differentiation
Traditional candidate approaches and more recently global microarray analysis are providing a comprehensive profile of Runx-directed gene expression that is linked to bone cell proliferation and differentiation . Target genes are both activated and repressed by Runx transcription factors and the promoter contexts of Runx recognition motifs permit discrimination between regulatory signals that determine physiological responsiveness during bone formation and remodeling. While mechanisms that impact on regulation of Runx2 expression and activity are only beginning to emerge, it is apparent that autologous control and post-translational modifications that include phosphorylation, acetylation and ubiquitination are also operative. Table 1 is a partial but representative summary of Runx target genes, indicating encoded proteins that contribute to skeletal phenotype commitment, growth control, bone extracellular matrix biosynthesis and mineralization, signal transduction, tissue-related transcriptional control and promoter architecture of skeletal genes. Included are genes that are essential for progression of differentiation at early stages of osteoblast differentiation (e.g. TGFb receptor 1, collagen alkaline phosphatase, collagenase 3 (Selvamurugan et al., 1998; Harada et al., 1999; Enomoto et al., 2000; Selvamurugan et al., 2000) and during the extracellular matrix mineralization (e.g. bone sialoprotein, dentin sialoprotein, osteopontin, and osteocalcin (Ducy et al., 1997; Harada et al., 1999; Javed et al., 1999; Chen et al., 2002) ). Runx2-mediated activation of Runx2 expression in postproliferative osteoblasts reflects autologous control. Runx2 control of target genes, both activation (e.g. osteocalcin (OC)) and suppression (e.g. BSP and Runx2 and autologous regulation), are facilitated by multiple Runx-responsive promoter elements (Ji et al., 1998; Drissi et al., 2000) and a multipartite organization of the Runx core and flanking motifs that provide a mechanistic basis for: (1) integration of Runx-sequence-dependent regulatory cues at strategically placed promoter sites; (2) activation (e.g. OC) or suppression (e.g. BSP , and Runx2 (Drissi et al., 2000) ) in a context and dosedependent biologically responsive manner; and (3) options for titrating Runx-sequence-dependent activity under a broad spectrum of biological circumstances. These structure-function inter-relationships are illustrated by promoter organization of Runx target genes where Runx elements are flanked or overlapped by binding elements or regulatory factors that include AP1, SMADS, C/EBP, PU.1, Myb and ETS (Zeng et al., 1997; Levanon et al., 1998; Pardali et al., 2000;  Hematopoietic genes T-cell receptor (TCR) a, b, and g subunits, Immunoglobulin m heavy chain, IgA1, IgH, cell surface glycoprotien (CD36) CD3e, CD4, CD-11a intergin, macrophage colony-stimulating factor receptor (MCSF-R1), defensin neutrophil protein 3 (NP3), enhancers of murine leukemia virus (MLV) polyomavirus and Moloney SL-3 virus, myeloperoxidase (MPO), neutrophil elastase, granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-3 (IL-3), B-cell-specific tyrosine kinase (BLK), Mouse Mast cell protease-6 (MMCP-6) and granzyme B-macrophage inflammatory protein 1-a (MIP-1a), l5, ARF/P14 Bone-related genes Osteocalcin (OC), TGF-b receptor-1 (TGFb R1), human vitamin D receptor (hVDR), estrogen receptor a,collagenase 3, prolactin, collagen, osteopontin (OP), bone sialo protein (BSP), alkaline phosphatase (ALP), osteoprotegrin (OPG), RANKL, C/EBPd, Runx2, dentin sialo protein (DSP), Galectin-3 Others multidrug resistance gene 1 (MDR-1), Rous sarcoma virus-long terminal repeats (RSV-LTR), P21, Bc12, and sex limited protein (SIP), longinterspersed nuclear elements-1 (Line-1), Epstein-BaP virus (EBV) latent membrane protein 1 (LMP-1) Runx-dependent genes are classified into two major classes. Many B-and T-cells-specific genes regulated by Runx transcription factors are grouped as 'Hematopoietic genes'. Markers of early and late stages of osteoblast differentiation and osteoclast-related genes regulated by Runx factors are designated as 'Bone-related genes'. 'Other' indicates genes not related to either of the two groupings. The abbreviations of genes described in text are shown D'Alonzo et al., 2002) . In many cases Runx motifs are necessary, but not sufficient, for transcriptional activation, suggesting that Runx2 promoter elements support the assembly of regulatory complexes that render target genes poised but not completely competent for the onset of expression Puig-Kroger et al., 2003) .
Runx control of osteoblast differentiation
The well-documented crosstalk between osteoblasts and osteoclasts is, at least in part, Runx mediated. Runx expression in osteoblasts impacts on osteoclast differentiation by influencing the expression of osteoprotegrin and RANK ligand (Thirunavukkarasu et al., 2000) . Striking examples of Runx2-mediated regulatory activity in non skeletal tissues are expressions in vascular endothelial cells, breast cancer cells and prostate cancer cells (reviewed in Cohen, 2001 ). Runx2 expression in endothelial cells has been linked with vascular calcification in artherosclerotic lesions (Mody et al., 2003) . Runx2 expression in breast cancer and prostate cancer cells appears to be related to expression of bone-related genes in the tumor cells that is coupled with osteolytic lesions in bone in vivo and recruitment of osteoclasts in bone marrow cell cultures.
Runx control of osteoblast proliferation
The involvement of Runx factors in supporting osteogenesis includes a central role in cell growth control. We have recently documented that Runx2 suppresses growth in osteoblasts and may support the transition stage from proliferation to exit from the cell cycle for phenotype commitment. The proliferative expansion of mesenchymal cells, osteoprogenitor cells and immature osteoblasts in response to mitotic growth factors is critical for normal skeletal development and bone formation. Osteoprogenitor expression requires a balance between growth and survival that is controlled by both growth regulatory cues (e.g. growth factors, cytokines, steroid hormones) and developmental factors . Cell growth control is mediated in part at the transcriptional level, because there are cell cycle stage-specific demands for de novo synthesis of proteins (e.g. histones, cyclins) . Yet, transcription factors that control proliferation of osteoblasts are minimally understood.
Runx2 is expressed in actively proliferating immature osteoblasts, but does not activate mature bone phenotypic genes in the mesenchymal progenitor cells, indicating that Runx2 has a biological function that precedes osteoblast maturation. Recent evidence from our laboratory is consistent with a requirement of Runx2 for stringent control of osteoblast proliferation (Pratap et al., 2003) . Calvarial-derived osteoprogenitors from Runx2 null and Runx2 DC mice, which express a protein lacking the normal C-terminus of Runx2, exhibit increased cell growth. Reintroduction of Runx2 into Runx2-deficient cells by adenoviral delivery restores physiological control of proliferation in osteoblasts, suggesting that Runx2 contributes to transcriptional control in immature osteoblasts to regulate proliferation.
The requirement for the C-terminal of Runx2 (Runx2 DC mice) in the control of osteoblast proliferation may be related in part by directly controlling genes involved in the cell cycle and growth control (Table 1) . Equally important, Runx2 interacts with a series of coregulatory proteins that integrate the activities of several cell proliferation-related signaling pathways (e.g. SMAD, Yes/Src, MAPK, FGF, pRb and Groucho/TLE) (Javed et al., 2000; Zaidi et al., 2002; Zhang et al., 2000b; Franceschi and Xiao, 2003) . More importantly, the pRb tumor suppressor protein modifies gene regulatory properties of Runx2 . In agreement with the cell growth regulatory function of Runx2, the levels of Runx2 are tightly regulated upon entry and exit from the cell cycle in osteoblasts. Runx2 is upregulated at the onset of quiescence in contact-inhibited or serumdeprived immature osteoblasts, while Runx2 levels are diminished to low levels upon re-entry into the cell cycle. Such findings, together with our genetic data, indicate a cell growth-suppressive function for Runx2 in mesenchymal bone cell progenitors. This cell growth regulatory activity of Runx2 is distinct from the genetic requirement for Runx2 in the final stages of osteoblast maturation and osteogenesis. We have observed elevated levels of cyclin E in Runx2-deficient mice. Runx2-dependent control of cyclins, CDK inhibitors, growth factors and growth factor receptors is particularly relevant, because together they function as components of cell signaling pathways that control cell cycle entry and/or the subsequent transitions between different cell cycle stages.
The characterization of Runx2 as a regulator of osteoblast proliferation is consistent with data obtained in other biological contexts where Runx2 acts as an oncogene (Cameron et al., 2003) . For example, Runx2 protein has independently been characterized as the DNA-binding component of a cellular heteromeric regulator of a DNA tumor virus PEBP2aA (Ogawa et al., 1993b ) and a factor encoded by a T-cell tumor integration locus in T-cell lymphomas or in Ha-ras transformed, but not normal NIH3T3 fibroblasts (Stewart et al., 1997) . Runx2 also cooperates with the c-myc gene in promoting formation of T-cell lymphomas (Fang et al., 2001) and is highly expressed in Ha-ras-transformed, but not normal NIH 3T3 fibroblasts. When activated by retroviral integration in T-cells, Runx2 acts as an oncogene that stimulates cell growth (Vaillant et al., 2002) . For example, forced expression of Runx2 in transgenic mice under the CD2 promoter interferes with early T-cells development to cause the expansion of a specific subset, and to predispose mice to lymphomas (Vaillant et al., 2002) . Furthermore, the indications that Runx2 functions in cell growth control is consistent with the properties of other Runx proteins. Mutations, deletions and deficiencies in the Runx1 and 3 genes have been linked to acute myelogenous leukemia (Speck and Stacy, 1995; Speck et al., 1999) or gastric cancer (Guo et al., 2002; Li et al., 2002) . The finding that Runx2 is required for stringent cell growth control in osteoblasts (Pratap et al., 2003) establishes that all three members of the Runx transcription factor family contribute to tissue-specific control of cell proliferation. Thus, there is accruing support for a dual function of Runx2 in osteogenesis. Runx2 promotes osteoblast maturation at a key developmental transition by attenuating osteoblast growth and functionally supporting exit from the cell cycle, while promoting lineage commitment and bone cell phenotype development by activating genes that are specific for mature osteoblasts.
Runx2-responsive gene expression within the three-dimensional context of nuclear architecture
Evidence is accumulating that the architectural organization of nucleic acids and regulatory proteins within the nucleus support functional inter-relationships between nuclear structure and gene expression. There is increasing acceptance that components of nuclear architecture (chromatin, nuclear scaffold) are functionally linked to the organization and sorting of regulatory information in a manner that permits selective utilization (Berezney et al., 1996; Zeng et al., 1997 Zeng et al., , 1998 Lamond and Earnshaw, 1998; Ma et al., 1998 Ma et al., , 1999 McNeil et al., 1998 McNeil et al., , 1999 Choi et al., 2001; DeFranco, 2002; Gasser, 2002) .
The Runx2 (AML3/Cbfa1/PEBP2aA) transcription factor and the bone-specific osteocalcin gene serve as paradigms for obligatory relationships between nuclear structure and physiological control of skeletal gene expression (Merriman et al., 1995; Banerjee et al., 2001; Ducy et al., 1997; Javed et al., 1999 Javed et al., , 2000 . The modularly organized promoter of the bone-specific osteocalcin gene contains proximal and distal regulatory elements that support basal, tissue-specific and growth factor, homeodomain, signaling protein, and steroid hormone-responsive transcriptional control (reviewed in (Demay et al., 1990; Markose et al., 1990; Bortell et al., 1992; Hoffmann et al., 1994; Tamura and Noda, 1994; Ducy and Karsenty, 1995; Guo et al., 1995; Merriman et al., 1995; Banerjee et al., 2001) ) (see Figure 3) . Modulation of osteocalcin gene expression during bone formation and remodeling requires physiologically responsive accessibility of these proximal and upstream promoter sequences to regulatory and coregulatory proteins as well as protein-protein interactions that integrate independent promoter domains. The nuclear matrix-associated Runx transcription factors contribute to the control of skeletal gene expression by sequencespecific binding to promoter elements of target genes and serving as scaffolds for the assembly and organization of coregulatory proteins that mediate biochemical and architectural control of promoter activity.
Runx-mediated chromatin remodeling facilitates promoter accessibility and integration of regulatory activities
It is well recognized that genomic DNA is packaged as chromatin. These 'bead on a string' structures designated nucleosomes are structurally remodeled to accommodate requirements for transcription, emphasizing the extent to which architectural organization of genes is causally related to functional activity. Simply stated, changes in the architectural properties of promoter elements determine effectiveness of gene regulatory sequences as substrates for interactions with regulatory factors. The regulatory and regulated parameters of chromatin remodeling and the rate-limiting steps in the relevant signaling cascades are being actively pursued and will unquestionably provide insight into skeletal gene regulatory mechanisms from structural and functional perspectives.
The Runx-dependent chromatin organization of the osteocalcin gene illustrates the dynamic remodeling of a promoter to accommodate the requirements for the phenotype-related developmental and steroid hormoneresponsive activity (Figure 3) . Nuclease digestion and ligation-mediated PCR analysis as well as in vitro nucleosome reconstitution studies establish the placement of nucleosomes in the proximal basal/tissuespecific domain and at the upstream vitamin D-responsive element, blocking accessibility of these promoter sequences to regulatory proteins in immature bone cells when this skeletal-restricted gene is suppressed (Breen et al., 1994; Montecino et al., 1994 Montecino et al., , 1996 Montecino et al., , 1999 Gutierrez et al., 2000; Paredes et al., 2002) . In response to developmental and skeletal regulatory signals the striking removal of a nucleosome and modifications in chromatin structure renders the proximal promoter of the OC gene accessible to regulatory and coregulatory proteins that support basal level activity Montecino et al., 1996 Montecino et al., , 1999 . Vitamin D enhancement of osteocalcin gene transcription is associated with the removal of the nucleosome at the upstream vitamin D-responsive element that permits binding of the vitamin D receptor-RXR heterodimer Javed et al., 1999; Paredes et al., 2002) . The retention of a nucleosome between the proximal and upstream enhancer domain reduces the distance between the basal and vitamin D-responsive element, and supports a promoter configuration that is conducive to proteinprotein interactions between the vitamin D receptor and the basal TFIIB transcription factor (Blanco et al., 1995; MacDonald et al., 1995; Guo et al., 1997) . Interaction of the vitamin D receptor at the distal promoter region of the bone-specific osteocalcin gene requires nucleosomal remodeling .
Thus, insight into the control of skeletal gene expression can be obtained from the understanding of Runx-mediated mechanisms that alter osteocalcin gene chromatin organization under biological conditions. Site-directed mutagenesis of osteocalcin genes that are genetically integrated in stable cell lines have established that Runx elements flanking the proximal and upstream promoter sequences are responsible for developmental and vitamin D-induced chromatin remodeling . Reduced CpG methylation is associated with transcriptional activation of the bone-specific osteocalcin gene in osteoblasts (Villagra et al., 2002) . In vitro and in vivo genetic approaches have demonstrated that Runx2 controls developmental and steroid hormone-responsive chromatin reconfiguration of the osteocalcin gene promoter Gutierrez et al., 2000) . Chromatin immunoprecipitation analyses have shown that developmental and vitamin D-linked remodeling of osteocalcin gene promoter organization is accompanied by acetylation of histones in the proximal basal and upstream vitamin D-responsive element domains (Shen et al., 2002 (Shen et al., , 2003 . This post-translational modification of histone proteins reduces the Figure 3 Remodeling of the Osteocalcin gene promoter during developmental progression of the osteoblast phenotype. The transcriptionally silent rat osteocalcin gene is schematically illustrated with nucleosomes placed in the proximal tissue-specific and distal enhancer region of the promoter (a). Factors such as Runx and p300 that support basal tissue-specific transcription are recruited to the OC gene promoter and are organized in proximal and distal promoter domains. Modifications in chromatin structure that mediate the assembly of the regulatory machinery for the nuclease hypersensitive sites reflect OC gene transcription. A positioned nucleosome resides between the proximal basal and distal enhancer regions of the promoter (b). In response to vitamin D, chromatin remodeling renders the upstream VDRE competent for binding the VDR/RXR heterodimer with its cognate element (c). Higher order chromatin organization permits crosstalk between basal transcription machinery and the vitamin D receptor complex that involves direct interactions of the vitamin D receptor, Runx2, p300 and TFIIB (d) tenacity of histone DNA interactions in a manner that is conducive to an open chromatin organization with increased access to regulatory factors. The most compelling evidence for a functional involvement of chromatin organization in skeletal gene expression is the obligatory relationship of dynamic changes in the biochemical and structural properties of osteocalcin gene promoter organization with competency for bone tissue-restricted and -enhanced transcription in response to vitamin D .
Yet, despite the cogent support for a central role of chromatin remodeling in transcriptional control of the osteocalcin gene, there are open-ended questions. It is not justifiable to extrapolate from these findings to conclude that all Runx-responsive genes that are activated and suppressed during skeletogenesis employ identical mechanisms. From a broader biological perspective there are multiple levels of control that must be mechanistically characterized to explain physiologically responsive regulation of chromatin structure within restricted and global genomic contexts.
Scaffolding of regulatory components for Runx-related combinatorial control of gene expression
Functional inter-relationships between nuclear structure and gene expression are strikingly reflected by dual recognition of regulatory proteins, such as Runx transcription factors, for interactions with both promoter elements and coregulatory proteins; such interactions modulate the structural and functional properties of targeted genes at microenvironments within the nucleus. Sequence-specific interactions with promoter elements result in the placement of Runx proteins at strategic sites where they provide scaffolds for protein-protein interactions, which mediate the organization of machinery for a broad spectrum of regulatory requirements. These include histone modifications and chromatin remodeling that establish competency for transcription factor binding and genomic conformations that interface activities at proximal and upstream promoter domains, as well as the integration of regulatory cues from signaling pathways that activate or suppress gene expression in a physiologically responsive manner. As a consequence, the Runx proteins are post-translationally modified (e.g. phosphorylated) to further influence the extent to which they engage in regulatory activity.
The complexity of Runx regulatory proteins that assemble as supercomplexes of transcriptional regulatory factors illustrates the potential impact on skeletal-related gene expression. Recent documentation that Runx proteins are components of a stable complex that includes basal transcription factors, chromatin remodeling factors, and histone modifying factors indicate the scope of Runx-mediated combinatorial control.
A key component of the Runx complex is the p300/ CBP coactivator, which functions as a transcriptional adaptor. Interactions with several transcription factors result in the formation of multimolecular complexes that regulate the expression of a broad spectrum of genes (Goodman and Smolik, 2000) . p300 contains a domain with intrinsic histone acetyltransferase (HAT) activity (Bannister et al., 1995; Ogryzko et al., 1996) , which has been implicated in chromatin structure alterations associated with modulation of gene expression (Spencer and Davie, 1999) . p300 interacts with additional proteins containing HAT activity that include P/CAF, SRC-1 and ACTR. A basis is thereby provided for formation of large multiprotein complexes that contribute multiple HAT activities with options for specificity (Chakravarti et al., 1996; Yang et al., 1996; Chen et al., 1997; Spencer et al., 1997; Torchia et al., 1997) . It has been established that Runx2 and p300 are components of the same nuclear complexes in osteoblastic cells (Sierra et al., 2003) . Furthermore, when recruited to the osteocalcin gene promoter by Runx2, p300 stimulates both basal and vitamin D-enhanced osteocalcin promoter activity. Thus interactions of Runx2 with p300 supports assembly of multisubunit complexes with several HAT-containing proteins at a series of regulatory regions of the bone-specific osteocalcin gene promoter. In a parallel manner, Kitabayashi et al. (1998) have shown that in myeloid cells Runx1, a homologue of the bone-specific Runx2, interacts with p300 and together upregulate myeloid-specific genes. It was also determined that a C-terminal region of the Runt domain in both Runx1 and 2, is critical for their interactions with p300 (Kitabayashi et al., 1998; Sierra et al., 2003) . Considering the high degree of homology between these two members of the Runx transcription factor family, it is likely that the structural determinants for Runx interactions with p300 are conserved. p300 can also be recruited to gene promoters by the transcription factor C/EBP (Oelgeschlager et al., 1996; Mink et al., 1997) . Interestingly, a C/EBP-responsive regulatory element has been identified in the proximal promoter region of the rat OC gene adjacent to the Runx2 site C . C/EBPb physically interacts with Runx2 and synergistically activates the osteocalcin promoter , suggesting that both proteins form a complex with p300 and together upregulate basal tissue-specific transcription. C/EBPb has additionally been shown to interact with ATP-dependent chromatin remodeling complexes of the SWI/SNF family (Kowenz-Leutz and Leutz, 1999), recruiting these complexes to promoter sequences and activating cell-specific expression.
In addition to functioning as transcriptional activators, Runx proteins suppress gene expression (transcription). Repression requires the recruitment of transcriptional repressors and corepressors with histone deacetylase activity (HDACs) to promoter regulatory elements of genes that are downregulated. Combinatorial control that dampens transcription is illustrated by the interaction of Runx2 with the transcriptional corepressors TLE/Groucho through a conserved VWRPY domain located at the C-terminus of the protein, which represses the expression of the bone-sialo protein (BSP) gene in osteoblastic cells (Javed et al., 2000) . Another example of combinatorial control that results in transcriptional suppression by Runx2 is the downregulation of the p21 CIP/WAF promoter in fibroblastic and osteoblastic cells. Here, HDAC6 interacts with a second repression domain that also resides in the C-terminal region of Runx2 and is recruited to chromatin by Runx2 (Westendorf et al., 2002) . Taken together, these results are consistent with combinatorial control that is mediated by Runx-dependent recruitment of coactivator and corepressor proteins that are associated with and organized as multiprotein complexes to activate or repress target genes in a physiologically responsive manner.
Taken together, these findings indicate that Runx factors engage in protein-DNA and protein-protein interactions that collectively determine the composition and organization of promoter regulatory complexes. The inclusion of chromatin remodeling activity in these multisubunit complexes provides a biochemical basis for conformational modifications of promoter elements as well as combinatorial specificity for transcription.
Transcription factors that function as scaffolds for interaction with coregulatory proteins provide an architectural basis for accommodating the combinatorial requirements of biological control. Combinatorial control supports replication, transcription and repair by two mechanisms. Context-dependent combinations and permutations of regulatory proteins are assembled into multipartite complexes that increase specificity. Scaffold-associated protein-DNA and protein-protein interactions permit integration of regulatory activities. Nuclear microenvironments are thereby organized, with gene promoters as focal points, where threshold concentrations of regulatory macromolecules are attained. The complexity that is achieved by these architecturally organized oligomeric factors can maximize options for responsiveness to diverse regulatory requirements for transient and long term biological control.
Intranuclear trafficking of Runx2 regulatory proteins to subnuclear sites that support transcription: to be in the right place at the right time There is a need to gain insight into mechanisms that direct skeletal factors to subnuclear sites where regulatory events occur. Association of osteoblast, myeloid, and lymphoid Runx transcription factors that mediate tissue-specific transcription with the nuclear matrix has permitted direct examination of mechanisms for targeting regulatory proteins to transcriptionally active subnuclear domains (Bae et al., 1993; Wang et al., 1993; Meyers et al., 1993 Meyers et al., , 1995 Meyers et al., , 1996 Nuchprayoon et al., 1994; Frank et al., 1995; Merriman et al., 1995; Satake et al., 1995; Banerjee et al., 1997 Banerjee et al., , 2001 Ducy et al., 1997; Zeng et al., 1997) . Both biochemical and immunofluorescence analyses have shown that Runx transcription factors exhibit a punctate nuclear distribution that is associated with the nuclear matrix in situ (Zeng et al., 1998 (Zeng et al., , 1997 Tang et al., 1999; Zaidi et al., 2004) . Taken together, these observations are consistent with the concept that the nuclear matrix is functionally involved in gene localization and in the concentration and subnuclear localization of regulatory factors (Dworetzky et al., 1992; Bidwell et al., 1993; van Wijnen et al., 1993; Blencowe et al., 1994; Mancini et al., 1994; Nickerson et al., 1995; Zeng et al., 1997) .
The initial indication that nuclear matrix association of Runx factors is required for maximal activity was provided by the observation that transcriptionally active Runx proteins associate with the nuclear matrix, but inactive C terminally truncated Runx proteins do not (Zeng et al., 1997; Choi et al., 1999; Javed et al., 2000; Zaidi et al., 2002) (Figure 3 ). This localization of Runx was established by biochemical fractionation and in situ immunofluorescence as well as by green fluorescent protein-tagged Runx proteins (Harrington et al., 2002) in living cells. Colocalization of Runx1, 2 and 3 at nuclear matrix-associated sites indicate that a common intranuclear targeting mechanism may be operative for the family of Runx transcription factors Javed et al., 2000; Harrington et al., 2002) . Variations in the partitioning of transcriptionally active and inactive Runx between subnuclear fractions permitted the development of a strategy to identify a region of the Runx transcription factors that directs the regulatory proteins to nuclear matrix-associated foci. Association of osteogenic and hematopoietic Runx proteins with the nuclear matrix is independent of DNA binding and requires a nuclear matrix targeting signal, a 31 amino-acid segment near the C-terminus that is distinct from nuclear localization signals (Zeng et al., 1997) . The nuclear matrix-targeting signal functions autonomously and is necessary as well as sufficient to direct the transcriptionally active Runx transcription factors to nuclear matrixassociated sites where gene expression occurs (Zeng et al., 1997) .
These findings indicate the mechanisms involved in the selective trafficking of proteins to specialized domains within the nucleus where they become components of functional regulatory complexes. At least two trafficking signals appear to be required for subnuclear targeting of Runx transcription factors; the first supports nuclear import (nuclear localization signal) and the second mediates association with the nuclear matrix (nuclear matrix targeting signal). The multiplicity of determinants for nuclear localization and alternative splicing of Runx messenger RNA may provide the requisite complexity to support targeting to specific sites within the nucleus in response to diverse biological conditions. Furthermore, because gene expression by Runx involves contributions by factors and coregulatory proteins that include CBFb (Ogawa et al., 1993a; Giese et al., 1995; Banerjee et al., 2001; Mao et al., 1999; Xie et al., 1999; Kundu et al., 2002; Miller et al., 2002; ) and C/EBP (Zhang et al., 1996; Gutierrez et al., 2002) , Groucho/TLE (Levanon et al., 1998; Javed et al., 2000 Javed et al., , 2001 , HES and SMAD (Zhang et al., 2000a; Zaidi et al., 2002) , Runx may facilitate recruitment of these factors to the nuclear matrix.
Properties of transcriptionally active subnuclear compartments
Association of genes and cognate factors with the nuclear matrix may support the formation and/or activities of nuclear domains that facilitate transcriptional control (Guo et al., 1995; Merriman et al., 1995; Nickerson et al., 1995; Berezney et al., 1996; Chen et al., 1996; Nardozza et al., 1996; Stein et al., 1996; Alvarez et al., 1997; Davie, 1997; Grande et al., 1997; Jackson, 1997; Lindenmuth et al., 1997) . Results from our laboratory indicate that the association of Runx transcription factors with the nuclear matrix is obligatory for activity (Zeng et al., 1998; Choi et al., 2001) . The promoter recognition function of the runt homology domain of Runx, and thus the consequential interactions with Runx-responsive genes, is essential for the formation of transcriptionally active foci containing Runx and RNA polymerase II that are nuclear matrix-associated (Zeng et al., 1998) . In addition, the nuclear matrix-targeting signal supports transactivation when associated with an appropriate promoter, and the transcriptional activity of the nuclear matrix-targeting signal depends on the association with the nuclear matrix (Zeng et al., 1998) . Taken together, targeting of Runx transcription factors to the nuclear matrix is important for their function and transcription. However, components of the nuclear matrix that function as acceptor sites remain to be established. Characterization of such nuclear matrix components will provide an additional dimension to characterizing molecular mechanisms associated with gene expressionthe targeting of regulatory proteins to specific spatial domains within the nucleus.
Subnuclear targeting and integration of signaling pathways
Gene expression during skeletal development and bone remodeling is controlled by a broad spectrum of regulatory signals that converge at promoter elements to activate or repress transcription in a physiologically responsive manner. The subnuclear compartmentalization of transcription machinery necessitates a mechanistic explanation for directing signaling factors to sites within the nucleus where gene expression occurs under conditions that support integration of regulatory cues. The interactions of YAP and SMAD coregulatory proteins with C-terminal segments of the Runx2 transcription factor permits assessment of requirements for recruitment of c-Src and BMP/TGFb-mediated signals to skeletal target genes. Our findings indicate that nuclear import of YAP and SMAD coregulatory factors is agonist dependent. However, there is a stringent requirement for fidelity of Runx subnuclear targeting for recruitment of these signaling proteins to active subnuclear foci transcriptionally. Our results demonstrate that the interactions and spatial-temporal organization of Runx and SMAD as well as YAP coregulatory proteins are essential for the assembly of transcription machinery that supports expression or repression of skeletal genes (Zaidi et al., 2004) . Competency for intranuclear trafficking of Runx proteins has similarly been functionally linked with the subnuclear localization and activity of TLE/Groucho coregulatory proteins (Javed et al., 2000) . These findings are consistent with Runx proteins serving as scaffolds for combinatorial interactions with coregulatory proteins that contribute to biological control and a requirement for intranuclear trafficking to complete the transduction and implementation of regulatory signals that are requisite for physiological responsiveness.
In vivo consequences of aberrant intranuclear trafficking of Runx transcription factors Using Runx2 and its essential role in osteogenesis as a model, we investigated the fundamental importance of subnuclear localization for tissue differentiation by deleting the intranuclear targeting signal via homologous recombination. Mice homozygous for the deletion (Runx2DC) do not form bone due to perturbed maturation or arrest of osteoblasts. Heterozygotes do not develop clavicles, but are otherwise normal. These phenotypes are indistinguishable from those of the Runx2 homozygous and heterozygous null mutants, indicating that the intranuclear targeting signal is a critical determinant for function. The expressed truncated Runx2DC protein enters the nucleus and retains normal DNA-binding activity, but shows complete loss of intranuclear targeting. These results establish that the multifunctional N-terminal region of the Runx2 protein is not sufficient for biological activity. Our results demonstrate that subnuclear localization of Runx factors in specific foci together with associated regulatory functions is essential for the control of Runxdependent genes involved in tissue differentiation during embryonic development . The importance of subnuclear localization of Runx transcription factors for biological control is further indicated by compromised subnuclear organization and activity of Runx1 hematopoietic regulatory proteins in acute myelogenous leukemia (McNeil et al., 1999) .
The regulated and regulatory parameters of Runx-mediated subnuclear organization: assembly and organization of nuclear microenvironments that govern transcriptional control Multiple lines of evidence suggest that components of nuclear architecture contribute both structurally and enzymatically to Runx-mediated control of gene expression during osteoblast differentiation. Sequences have been identified that direct Runx transcription factors to nuclear matrix-associated sites that support transcription in a cell cycle-dependent manner . Insight is thereby provided into mechanisms linked to the assembly and activities of subnuclear domains where transcription occurs. In a restricted sense, the foundation has been provided for experimentally addressing intranuclear trafficking of gene regulatory factors and control of association with the nuclear matrix to establish and sustain domains that are competent for transcription. In a broader context, there is a growing appreciation for involvement of nuclear architecture in a dynamic and bidirectional exchange of gene transcripts and regulatory factors between the nucleus and cytoplasm, as well as between regions and structures within the nucleus (Lamond and Earnshaw, 1998; Wei et al., 1998 Wei et al., , 1999 Stein et al., 2000a, b; Gasser, 2002) .
It would be presumptuous to propose a single model to account for the specific pathways that direct transcription factors to sites within the nucleus that support transcription. However, findings suggest that parameters of nuclear architecture functionally interface with components of transcriptional control. The involvement of nuclear matrix-associated transcription factors with the recruitment of regulatory components to modulate transcription remains to be defined. Working models that serve as frameworks for experimentally addressing components of transcriptional control within the context of nuclear architecture can be compatible with mechanisms that involve architecturally or activitydriven assembly of transcriptionally active intranuclear foci. The diversity of targeting signals must be established to evaluate the extent to which regulatory discrimination is mediated by encoded intranuclear trafficking signals. It will additionally be important to biochemically and mechanistically define the checkpoints, which are operative during subnuclear distribution of regulatory factors, and the editing steps, which are invoked to ensure that structural and functional fidelity of nuclear domains, where replication and expression of genes occur. There is emerging recognition that the placement of regulatory components of gene expression must be temporally and spatially coordinated to mediate biological control optimally. The physiologically dynamic mechanisms that are operative in the temporal/spatial intranuclear organization of regulatory complexes are illustrated by the mitotic segregation of Runx transcription factors in a manner that renders the Runx transcriptional machinery competent to support gene expression postmitotically . It is realistic to anticipate that further understanding of mechanisms that position genes and regulatory factors for establishment and maintenance of the bone cell phenotype will clarify nuclear structure-function interrelationships that are operative during Runx-directed osteoblast differentiation and modulation of regulatory activity.
